SCHEMBL7499013

SCHEMBL7499013

CCCN(CCC)C1CCc2cccc(O)c2C1C

nearest known ligand 1.00 ✓ in ChEMBL — recovers established targets

Predicted protein targets (top 1)

geneUniProtsupporting neighboursconfidence
DRD2 P14416 7/20 1.00

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL5945687 1.00 DRD2 (1.00) DRD2
SCHEMBL5945738 1.00 DRD2 (1.00) DRD2
SCHEMBL8672337 0.84 DRD2 (0.72) DRD2
SCHEMBL8672335 0.84 DRD2 (0.72) DRD2
SCHEMBL8672340 0.84 DRD2 (0.72) DRD2
SCHEMBL8875861 0.83 DRD2 (0.71) DRD2
SCHEMBL8875869 0.83 DRD2 (0.71) DRD2
SCHEMBL8875872 0.83 DRD2 (0.71) DRD2
Hydrochloric Acid SCHEMBL7926859 0.83 DRD2 (0.70) DRD2
Hydrochloric Acid SCHEMBL7926863 0.83 DRD2 (0.70) DRD2

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 26 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
US-20020035998-A1 Method for treatment of cancer and infectious disease HELLSTRAND KRISTOFFER (SE) 2002-03-28 US claimed
US-6305380-B1 ADMINISTERING HISTAMINE AGONIST OR HT3 RECEPTOR ANTAGONIST TO ACTIVATE NATURAL KILLER CELLS AND TREAT VIRAL DISEASES MAXIM PHARMACEUTICALS, INC. 2001-10-23 US claimed
EP-0652768-B1 A pharmaceutical preparation for the synergistic activation of natural killer cells MAXIM PHARM INC (US) 2000-05-03 EP claimed
US-5728378-A ANTITUMOR AND ANTIVIRUS AGENTS MAXIM PHARMACEUTICALS, INC. (US) 1998-03-17 US claimed
US-20020035998-A1 Method for treatment of cancer and infectious disease HELLSTRAND KRISTOFFER (SE) 2002-03-28 US disclosed
US-6331636-B1 TREATMENT OF CENTRAL NERVOUS SYSTEM DISORDERS, DIABETES, HYPERTENSION, IMPOTENCY, APPETITE CONTROL THE UPJOHN COMPANY 2001-12-18 US disclosed
US-6305380-B1 ADMINISTERING HISTAMINE AGONIST OR HT3 RECEPTOR ANTAGONIST TO ACTIVATE NATURAL KILLER CELLS AND TREAT VIRAL DISEASES MAXIM PHARMACEUTICALS, INC. 2001-10-23 US disclosed
US-6155266-A Method for treatment of cancer and infectious disease MAXIM PHARMACEUTICALS, INC. (US) 2000-12-05 US disclosed
EP-0652768-B1 A pharmaceutical preparation for the synergistic activation of natural killer cells MAXIM PHARM INC (US) 2000-05-03 EP disclosed
US-6003516-A Method for treatment of cancer and infectious disease MAXIM PHARMACEUTICALS, INC. (US) 1999-12-21 US disclosed
EP-0476016-B1 CNS active 8-heterocyclyl-2-aminotetralin derivatives UPJOHN CO (US) 1998-10-28 EP disclosed
US-5728378-A ANTITUMOR AND ANTIVIRUS AGENTS MAXIM PHARMACEUTICALS, INC. (US) 1998-03-17 US disclosed
EP-0586525-A1 CARBOXAMIDO-(1,2N)-CARBOCYCLIC-2-AMINOTETRALIN DERIVATIVES. UPJOHN CO (US) 1994-03-16 EP disclosed
EP-0552246-A1 THERAPEUTICALLY USEFUL 2-AMINOTETRALIN DERIVATIVES PHARMACIA & UPJOHN COMPANY (US) 1993-07-28 EP disclosed
WO-1992021654-A2 CARBOXAMIDO-(3,2N)-CARBOCYCLIC-2-AMINOTETRALIN DERIVATIVES THE UPJOHN COMPANY (US) 1992-12-10 WO disclosed
WO-1992020655-A1 CARBOXAMIDO-(1,2N)-CARBOCYCLIC-2-AMINOTETRALIN DERIVATIVES THE UPJOHN COMPANY (US) 1992-11-26 WO disclosed
WO-1992006967-A1 THERAPEUTICALLY USEFUL 2-AMINOTETRALIN DERIVATIVES THE UPJOHN COMPANY (US) 1992-04-30 WO disclosed
EP-0476016-A1 THERAPEUTICALLY USEFUL 2-AMINOTETRALIN DERIVATIVES PHARMACIA & UPJOHN COMPANY (US) 1992-03-25 EP disclosed
WO-1991000856-A2 (1,2N) AND (3,2N)-CARBOCYCLIC-2-AMINO TETRALIN DERIVATIVES THE UPJOHN COMPANY (US) 1991-01-24 WO disclosed
WO-1990015047-A1 THERAPEUTICALLY USEFUL 2-AMINOTETRALIN DERIVATIVES THE UPJOHN COMPANY (US) 1990-12-13 WO disclosed